Role of Heparin in Tumor Cell-Induced Platelet Aggregation

Summary

B16 mouse melanoma cell lines (B16F1, B16F10 and B16BL6) were able to induce platelet aggregation, and concomitant release of ATP in heparinized platelet-rich plasma (PRP). In citrated PRP, these tumor cells did not induce platelet aggregation. Addition of heparin to citrated PRP enabled these tumor cells to induce aggregation. In heparinized PRP, platelet aggregates induced by B16F10 cells were dissociated by the addition of either 4 mM EDTA, 10 mM CaCl₂ or 0.1 μg/ml protamine sulfate. B16F10-induced aggregation in heparinized PRP was inhibited by preincubation with anti-fibronectin antibody, but not with antifibrinogen or anti-von Willebrand factor antibodies. B16F10 cells induced aggregation in washed platelet suspension with the addition of heparinized platelet-poor plasma (PPP). Cryoprecipi-tate from human plasma showed the same effect in the presence of heparin if substituted for PPP. The mixture of purified fibronectin, von Willebrand factor, fibrinogen and heparin were less effective than cryoprecipitate on B16F10-induced aggregation of washed platelets. The results suggest that an interaction between fibronectin and heparin may be important in tumor cell-induced aggregation.

Keywords

Platelet aggregation - Tumor cell - Heparin - Fibronectin

• References

• 1 Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S. Platelet-tumor interaction in mice. The role of platelets in the spread of malignant disease. Int J Cancer 1973; 11: 704-718
• 2 Bastida E, Ordinas A, Giardina SL, Jamieson GA. Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase. Cancer Res 1982; 42: 4348-4352
• 3 Bastida E, Ordinas A, Jamieson GA. Differing platelet aggregating effects by two tumor cell lines: absence of role for platelet-derived ADP. Am J Hematol 1980; 11: 367-378
• 4 Gasic GJ, Gasic TB, Jimenez SA. Platelet aggregation material in mouse tumor cells. Removal and regeneration. Lab Invest 1977; 36: 413-419
• 5 Gasic GJ, Koch PA G, Hsu B, Gasic TB, Niewiarowski S. Thrombogenic activity of mouse and human tumors: effects on platelets, coagulation and fibrinolysis, and possible significance for metastases. Z Krebsforsch Klin Onkol 1976; 86: 263-277
• 6 Hara Y, Steiner M, Baldini MG. Characterization of the platelet-aggregating activity of tumor cells. Cancer Res 1980; 40: 1217-1222
• 7 Karpatkin S, Smerling A, Pearlstein E. Plasma requirement for the aggregation of rabbit platelets by an aggregating material derived from SV40-transformed 3T3 fibroblasts. J Lab Clin Med 1980; 96: 994-1001
• 8 Pearlstein E, Ambrogio C, Gasic GJ, Karpatkin S. Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-I,5-pentanediyl)-amide. Cancer Res 1981; 41: 4535-4539
• 9 Pearlstein E, Cooper LB, Karpatkin S. Extraction and characterization of a platelet-aggregating material from SV40-transformed mouse 3T3 fibroblasts. J Lab Clin Med 1979; 93: 332-344
• 10 Pearlstein E, Salk PL, Yogeeswaran G, Karpatkin S. Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line. Proc Natl Acad Sci USA 1980; 77: 4336-4339
• 11 Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: A factor X activiting procoagulant from malignant tissue. Thromb Res 1975; 6: 127-137
• 12 Curatolo L, Colucci M, Cambini AL, Poggi A, Morasca L, Donati MB, Semeraro N. Evidence that cells from experimental tumors can activate coagulation factor X. Br J Cancer 1979; 40: 228-232
• 13 Gordon SG, Franks JJ, Lewis BJ. Comparison of procoagulant activities in extracts of normal and malignant human tissue. J Natl Cancer Inst 1979; 62: 773-777
• 14 Lerner WA, Pearlstein E, Ambrogio C, Karpatkin S. A new mechanism for tumor-induced platelet aggregation. Comparison with mechanisms shared by other tumors with possible pharmacologic strategy toward prevention of metastases. Int J Cancer 1983; 31: 463-469
• 15 Tohgo A, Tanaka NG, Ogawa H. Platelet-aggregating activities of metastasizing tumor cells. III. Platelet aggregation as resulting from thrombin generation by tumor cells. Invasion Metastasis 1985; 5: 96-105
• 16 Fidler IJ. Selection of successive tumour lines for metastasis. Nature (New Biology) 1973; 242: 148-149
• 17 Hart IR. Selection and characterization of invasive variant of the B16 melanoma. Am J Pathol 1979; 97: 587-600
• 18 Poste G, Hart IR, Fidler IJ. In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res 1980; 40: 1636-1644
• 19 Kirby EP, Mills DC B. The effects of chymotrypsin and of ADP on the binding site for bovine factor VIII on human platelets. Thromb Haemostas 1981 46. 304 (Abstr)
• 20 Yamazaki H, Suzuki H, Yamamoto N, Tanoue K. Electron microscopic observation on platelet aggregation induced by cationized ferritin. Blood 1984; 63: 439-447
• 21 Hayashi M, Yamada KM. Divalent cation modulation of fibronectin binding to heparin and DNA. J Biol Chem 1982; 257: 5263-5267
• 22 Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo survival of human factor VIII/vWF protein. J Biol Chem 1977; 252: 5538-5546
• 23 Engvall E, Ruoslahti E. Binding of soluble form of fibroblast surface protein, fibronectin, to collagen. Int J Cancer 1977; 20: 1-5
• 24 Mosesson MW, Umfleet RA. The cold-insoluble globulin of human plasma. I. Purification, primary characterization, and relationship to fibrinogen and other cold-insoluble fraction components. J Biol Chem 1970; 245: 5728-5736
• 25 Jennings LK, Phillips DR. Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb—III complex. J Biol Chem 1982; 257: 10458-10466
• 26 Onoue K, Yagi Y, Pressman D. Multiplicity of antibody proteins in rabbit anti-p-azobenzenearzonate sera. J Immunol 1964; 92: 173-182
• 27 Bastida E, Escolar G, Ordinas A, Steven L, Giardina SL, Jamieson GA. Effects of divalent cations on the interaction of platelets with tumor cells: Aggregation and perfusion studies with two homologous human systems. J Lab Clin Med 1985; 106: 68-74
• 28 Hayashi M, Schlesinger DH, Kennedy DW, Yamada KM. Isolation and characterization of a heparin-binding domain of cellular fibronectin. J Biol Chem 1980; 255: 10017-10020
• 29 Yamada KM, Kennedy WD, Kimata K, Pratt RM. Characterization of fibronectin interactions with glycosaminoglycans and identification of active proteolytic fragments. J Biol Chem 1980; 255: 6055-6063
• 30 Plow EF, Ginsberg MH. Specific and saturable binding of plasma fibronectin to thrombin-stimulated human platelets. J Biol Chem 1981; 256: 9477-9482
• 31 Ginsberg MH, Forsyth J, Lightsey A, Chedak J, Plow EF. Reduced surface expression and binding of fibronectin by thrombin-stimulated thrombasthenic platelets. J Clin Invest 1983; 71: 619-624
• 32 Plow EF, Marguerie GA, Ginsberg MH. Fibronectin binding to thrombin-stimulated platelets: Evidence for fibrin(ogen) independent and dependent pathways. Blood 1985; 66: 26-32
• 33 Gardner JM, Hynes RO. Interaction of fibronectin with its receptor on platelets. Cell 1985; 42: 439-448
• 34 Plow EF, Pierschbacher MD, Rouslahti E, Marguerie GA, Ginsberg MH. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 1985; 82: 8057-8061
• 35 Gartner TK, Bennett JS. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. J Biol Chem 1985; 260: 11891-11894
• 36 Yamamoto K, Yamamoto N, Kitagawa H, Tanoue K, Kosaki G, Yamazaki H. Localization of a thrombin-binding site on human platelet membrane glycoprotein lb determined by a monoclonal antibody. Thromb Haemostas 1986; 55: 162-167